
Author's Accepted Manuscript

The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials

Zhicai Zhang, Feifei Pu, Zengwu Shao



www.elsevier.com/locate/ibo

PII: S2212-1374(16)30085-9

DOI: https://doi.org/10.1016/j.jbo.2017.09.003

Reference: JBO146

To appear in: Journal of Bone Oncology

Received date: 4 September 2016 Revised date: 31 March 2017 Accepted date: 18 September 2017

Cite this article as: Zhicai Zhang, Feifei Pu and Zengwu Shao, The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials, *Journal of Bone Oncology*, https://doi.org/10.1016/j.jbo.2017.09.003

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

The skeletal-related events of denosumab versus zoledronic acid in patients with

bone metastases: a meta-analysis of randomized controlled trials

Zhicai Zhang^{a1}, Feifei Pu^{b1}, Zengwu Shao^{a*}

^aDepartment of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of

Science and Technology, Wuhan, Hubei, China

^bDepartment of Orthopedics, Wuhan No.1 Hospital, Wuhan Integrated TCM & Western Medicine

Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan,

Hubei, China

zhicaizhang@126.com

pufeifeiemail@163.com

szwjj@medmail.com.cn

*Corresponding author.

Abstract

Objective

The meta-analysis was used to evaluate the skeletal-related events (SREs) and efficacy of

denosumab versus zoledronic acid (ZA) in patients with bone metastases.

Methods

The data of this meta-analysis study were searched from PUBMED, EMBASE, Cochrane Library,

Web of Science with Conference Proceedings, Elsevier and China National Knowledge

Infrastructure (CNKI) databases till August 2017. Two independent reviewers reviewed the

reference lists of relevant articles. The fixed-effects model and random-effects model were used to

summarize relative estimates and 95% confidence intervals (CIs) according to the heterogeneity of

the included studies.

Results

Three randomized controlled trials (RCTs) including 4050 patients were identified in this

meta-analysis study. The pooled analysis showed that denosumab could significantly reduce SREs,

series SREs [Odds Ratio (OR) = 0.84; 95% CI, 0.74-0.95, I² = 0%, P = 0.008] in patients with

bone metastases as compared with ZA. Similar results of spinal cord compression SRE and

These authors contributed equally to this work.

Download English Version:

https://daneshyari.com/en/article/8453185

Download Persian Version:

https://daneshyari.com/article/8453185

<u>Daneshyari.com</u>